Skip to main content
OpenTrials
Completed

NCT Number: NCT02411500

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males

The primary objective of this study is to evaluate the pharmacokinetics of various TRV734 formulations in healthy male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

San Antonio, Texas, 78209, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy as determined by a responsible physician or trained qualified designee
  • Males: 18 - 55 years inclusive at screening
  • Capable of giving written informed consent

Exclusion criteria

  • Clinically significant conditions or history of fainting or syncope
  • Medical or psychiatric illness that could interfere with the completion of treatment and follow up
  • Major surgery within 4-weeks of screening
  • Known difficulty with obtaining intravenous access
  • History of sensitivity to the study medication, or intolerance to opioids, or a history of medication or other allergy that contraindicates their participation
  • Use of prescription or non-prescription medications
  • History of excessive alcohol use
  • History of drug abuse within 6 months of screening
  • Use of any illegal drug within 30 days of screening and throughout participation in the study
  • History of smoking or use of nicotine containing products within 3 months of screening and throughout participation in the study
  • Donation of blood or plasma 4 weeks prior to dosing
  • Participation in a clinical trial and has received medication within 30 days
  • Weight <50 kg or BMI outside range of 18-32 kg/m2
  • Positive for HIV antibody, hepatitis B virus surface antigen, or hepatitis C virus
  • Unwillingness to abstain from sexual intercourse with a pregnant or lactating woman and, if engaging in sexual intercourse with a female partner of child-bearing potential, use a condom and spermicide, in addition to having their female partner use another form of contraception, and abstain from sperm donation

Treatment and study plan

TRV734

Drug

Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.

Primary outcomes

  1. Evaluate the maximum observed plasma concentration (Cmax)

    Time frame: 9-days

  2. Evaluate the time at which the maximum plasma concentration was observed (tmax)

    Time frame: 9-days

  3. Evaluate the area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-t)

    Time frame: 9-days

  4. Evaluate the area under the plasma concentration-time curve from time 0 to time extrapolated to infinity (AUC0-inf)

    Time frame: 9-days

  5. Evaluate the apparent elimination half-life (t1/2)

    Time frame: 9-days

  6. Evaluate the apparent clearance (CL/F)

    Time frame: 9-days

Secondary outcomes

  1. Safety and tolerability as measured by adverse events

    Time frame: 9-days

  2. Safety and tolerability as measured by clinical observations

    Time frame: 9-days

  3. Safety and tolerability as measured by 12-lead ECGs

    Time frame: 9-days

  4. Safety and tolerability as measured by cardiac telemetry monitoring

    Time frame: 9-days

  5. Safety and tolerability as measured by vital signs (BP, HR, RR and oral temperature)

    Time frame: 9-days

  6. Safety and tolerability as measured by oxygen saturation

    Time frame: 9-days

  7. Safety and tolerability as measured by safety laboratory tests

    Time frame: 9-days

Sponsors and collaborators

Lead sponsor

Trevena Inc.

Industry

Registry information

Official study title

A Randomized, Open Label, Four Period, Cross-Over Study to Evaluate the Pharmacokinetics of Single Doses of Various TRV734 Formulations in Healthy Male Subjects

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Apr 8, 2015
Registry last updated
Nov 18, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.